Although early studies mostly focused on cancer cells with germ line mutations of BRCA genes, PARP inhibitors have been shown to inhibit the growth of breast cancer cells, regardless of their BRCA status [39], suggesting that chemotherapy using PARP inhibitors is useful for other cancer cells with aberrant DNA damage responses. Here, PARP1 is linked to breast carcinoma.